TWIST overexpression predicts biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy

References

• Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481–8.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.
   PubMed Web of Science ®Google Scholar
• Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250–61.
   PubMed Web of Science ®Google Scholar
• Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 2009;55:1321–30.
   PubMed Web of Science ®Google Scholar
• Epstein JI, Allsbrook WCJr, Amin MB, Egevad LL; ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228–42.
   PubMed Web of Science ®Google Scholar
• Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001;58:843–8.
   PubMed Web of Science ®Google Scholar
• Martin NE, Mucci LA, Loda M, Depinho RA. Prognostic determinants in prostate cancer. Cancer J 2011;17:429–37.
   PubMed Web of Science ®Google Scholar
• Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927–39.
   PubMed Web of Science ®Google Scholar
• Yang J, Mani SA, Weinberg RA. Exploring a new twist on tumor metastasis. Cancer Res 2006;66:4549–52.
   PubMed Web of Science ®Google Scholar
• Kang Y, Massague J. Epithelial–mesenchymal transitions: twist in development and metastasis. Cell 2004;118:277–9.
   PubMed Web of Science ®Google Scholar
• Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev 1999;13:2207–17.
   PubMed Web of Science ®Google Scholar
• Cheng GZ, Chan J. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. 2007;67:1979–87.
   Google Scholar
• Soini Y, Tuhkanen H, Sironen R, Virtanen I, Kataja V, Auvinen P, et al. Transcription factors zeb1, twist and snai1 in breast carcinoma. BMC Cancer 2011;11:73.
   PubMed Web of Science ®Google Scholar
• Yuen HF, Chua CW, Chan YP, Wong YC, Wang X, Chan KW. Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer. Histopathology 2007;50:648–58.
   PubMed Web of Science ®Google Scholar
• Bokobza SM, Ye L, Kynaston H, Jiang WG. Growth and differentiation factor 9 (GDF-9) induces epithelial–mesenchymal transition in prostate cancer cells. Mol Cell Biochem 2011;349:33–40.
   PubMed Web of Science ®Google Scholar
• Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, et al. Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene 2010;29:237–50.
   PubMed Web of Science ®Google Scholar
• Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 2005;65:5153–62.
   PubMed Web of Science ®Google Scholar
• Behnsawy HM, Miyake H, Harada K, Fujisawa M. Expression patterns of epithelial–mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy. BJU Int 2013;111:30–7.
   PubMedGoogle Scholar
• Mori R, Wang Q, Quek ML, Tarabolous C, Cheung E, Ye W, et al. Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer. Anticancer Res 2008;28:425–30.
   PubMed Web of Science ®Google Scholar
• Theodoropoulos VE, Tsigka A, Mihalopoulou A, Tsoukala V, Lazaris AC, Patsouris E, et al. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications. Urology 2005;66:897–902.
   PubMed Web of Science ®Google Scholar
• Takeda H, Akakura K, Masai M, Akimoto S, Yatani R, Shimazaki J. Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer 1996;77:934–40.
   PubMed Web of Science ®Google Scholar
• Shukla-Dave A, Hricak H, Ishill N, Moskowitz CS, Drobnjak M, Reuter VE, et al. Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles. Clin Cancer Res 2009;15:3842–9.
   PubMed Web of Science ®Google Scholar
• Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol 2004;28:928–34.
   PubMed Web of Science ®Google Scholar
• Walz J, Chun FK, Klein EA, Reuther A, Saad F, Graefen M, et al. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol 2009;181:601–7; discussion 607–8.
   PubMed Web of Science ®Google Scholar
• Sobin LH, Wittekind C, Gospodarowicz MK. International Union Against Cancer. TNM classification of malignant tumours. 7th ed. 2009 ed Oxford: Wiley-Blackwell; 2010.
   Google Scholar
• Karvonen U, Kallio PJ, Janne OA, Palvimo JJ. Interaction of androgen receptors with androgen response element in intact cells. Roles of amino- and carboxyl-terminal regions and the ligand. J Biol Chem 1997;272:15973–9.
   PubMed Web of Science ®Google Scholar
• Merikallio H, Paakko P, Salmenkivi K, Kinnula V, Harju T, Soini Y. Expression of snail, twist, and Zeb1 in malignant mesothelioma. APMIS 2013;121:1–10.
   PubMed Web of Science ®Google Scholar
• Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079–92.
   PubMed Web of Science ®Google Scholar
• Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY, Yang WH, et al. Bmi1 is essential in Twist1-induced epithelial–mesenchymal transition. Nat Cell Biol 2010;12:982–92.
   PubMed Web of Science ®Google Scholar
• Jouppila-Matto A, Narkio-Makela M, Soini Y, Pukkila M, Sironen R, Tuhkanen H, et al. Twist and snai1 expression in pharyngeal squamous cell carcinoma stroma is related to cancer progression. BMC Cancer 2011;11:350.
   PubMed Web of Science ®Google Scholar
• Riaz M, Sieuwerts AM, Look MP, Timmermans MA, Smid M, Foekens JA, et al. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes. Breast Cancer Res 2012;14:R123.
   Web of Science ®Google Scholar
• Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJJr, Lilja H, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006;24:3973–8.
   PubMed Web of Science ®Google Scholar